Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer

  1. Martín, M.
  2. Rodríguez-Lescure, A.
  3. Ruiz, A.
  4. Alba, E.
  5. Calvo, L.
  6. Ruiz-Borrego, M.
  7. Munárriz, B.
  8. Rodríguez, C.A.
  9. Crespo, C.
  10. De Alava, E.
  11. López García-Asenjo, J.A.
  12. Guitián, M.D.
  13. Almenar, S.
  14. González-Palacios, J.F.
  15. Vera, F.
  16. Palacios, J.
  17. Ramos, M.
  18. Gracia Marco, J.M.
  19. Lluch, A.
  20. Alvarez, I.
  21. Seguí, M.A.
  22. Mayordomo, J.I.
  23. Antón, A.
  24. Baena, J.M.
  25. Plazaola, A.
  26. Modolell, A.
  27. Pelegrí, A.
  28. Mel, J.R.
  29. Aranda, E.
  30. Adrover, E.
  31. Álvarez, J.V.
  32. García Puche, J.L.
  33. Sánchez-Rovira, P.
  34. Gonzalez, S.
  35. López-Vega, J.M.
  36. Show all authors +
Journal:
Journal of the National Cancer Institute

ISSN: 1460-2105 0027-8874

Year of publication: 2008

Volume: 100

Issue: 11

Pages: 805-814

Type: Article

DOI: 10.1093/JNCI/DJN151 GOOGLE SCHOLAR lock_openOpen access editor

Sustainable development goals